Sunitinib Myths: — Hair Colour, Dose Cuts and 'Weaker Treatment'

My hair has turned grey or light yellow — sunitinib must be harming my body

Hair colour change on sunitinib is a direct pharmacological effect on melanocytes, the pigment-producing cells in hair follicles. It has been described in published case series and is not classified as a toxicity or a sign of harm. It is natural to be alarmed by any visible body change. The evidence says this one is not a warning — it is a sign the drug is circulating and reaching the follicle.

My dose has been cut — the treatment is now weaker and less likely to work

Dose modification for sunitinib is described in NCCN and ASCO guidance as a standard management strategy, not a compromise. The drug is started at a dose calibrated for a population average; once your individual response is known, your oncologist adjusts. Data reported in oncology literature indicate that patients who receive dose reductions for toxicity management can have outcomes comparable to those who remain on the starting dose. Managing side effects is what keeps you on treatment.

Sunitinib is chemotherapy in tablet form

Sunitinib is a tyrosine kinase inhibitor — a targeted therapy, not chemotherapy. It works by blocking specific receptor proteins, including VEGFR and PDGFR, that tumour cells use to grow and build a blood supply. Chemotherapy works differently: it interferes with cell division broadly, which is why it causes the pattern of side effects it does. Sunitinib has a different side effect profile for exactly this reason. Both treat cancer, but the mechanisms are not the same.

My skin has gone yellow or orange — I must have jaundice

A yellow-orange tint to the skin is a recognised effect of sunitinib called xanthoderma, caused by carotenoid pigment accumulation. It is not the same as jaundice. In jaundice the whites of the eyes also yellow and other symptoms are usually present. Xanthoderma typically affects the skin while the sclera remains white. Always report colour changes to your team so they can assess it directly — but skin yellowing alone with clear eyes is most likely xanthoderma, not a liver problem.

During the two weeks off sunitinib, my cancer is not being treated

The standard sunitinib schedule — four weeks on, two weeks off — is the regimen as designed, per NCCN guidelines. The rest period allows normal tissues to recover from the drug's effects. The anti-tumour response does not simply stop the moment you take the last tablet in a cycle. The off weeks are built into the treatment design, not a gap in it. Some patients are managed on a two-weeks-on, one-week-off schedule instead — your oncologist will specify which applies to you.